Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00587691Phase 1Completed

Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis

Role: lead

NCT01684761Phase 2Completed

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Role: lead

NCT00595920Phase 2Terminated

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

Role: lead

NCT00245622Phase 2Completed

Autologous T Cell Vaccine (TCV) for Multiple Sclerosis

Role: lead

All 4 trials loaded